Collection

UKHSA evidence reviews

Evidence reviews conducted by the All Hazards Public Health Response Evidence Review team and the Science Evidence Review team within UKHSA.

From:
UK Health Security Agency
Published
2 March 2023
Last updated
23 January 2025 — See all updates

Mpox

Environmental hazards

Influenza

Health equity and inclusion health

Climate change

COVID-19

Other infections

Updates to this page

Published 2 March 2023
Last updated 23 January 2025 + show all updates

  1. Added 3 new evidence reviews 'Mpox incubation and infectious periods', 'Mpox asymptomatic and pre-symptomatic transmission' and 'Mpox routes of transmission'. Also added 'Mpox: adherence and barriers to isolation'.

  2. Moved environmental hazards section to the top.

  3. Added environmental hazards section.

  4. Added 'Clostridioides difficile diagnostic test accuracy' and 'Vaginal oestrogen for prevention of primary urinary tract infections' to Other infections.

  5. Added 'Influenza A (H5)', 'Influenza A (H5) in non-human mammals' and 'Influenza A (H5 or H7) and conjunctivitis'.

  6. Added 'Influenza A (H1N1v and H1N2v)'.

  7. Added 'Interventions to reduce harms for people who inject drugs in prisons'

  8. Added climate change and health equity review.

  9. Added 'Communal accommodation settings'.

  10. Added 'Communal accommodation settings'.

  11. Added 'Chapare virus'.

  12. Added The global epidemiology of sporotrichosis: A rapid review.

  13. Added COVID-19: non-pharmaceutical interventions to reduce transmission.

  14. Added Tuberculosis (TB): prevalence of latent infection.

  15. Added evidence reviews conducted during the COVID-19 pandemic by the COVID-19 rapid evidence service.

  16. Added 'COVID-19: effectiveness of N95 masks in community settings' and 'COVID-19 Omicron variant: infectious period and asymptomatic and symptomatic transmission'.

  17. First published.

Contents